Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Castagna

Showing results (61-70 of 91) with videos related to

Pageof 10
Sort By:
Leukemia|September 20, 2014
Allogeneic and autologous stem cell transplantation for hepatosplenic T-cell lymphoma: a retrospective study of the EBMT Lymphoma Working PartyA Tanase, N Schmitz, H Stein, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society|February 5, 2015
Infections after T-replete haploidentical transplantation and high-dose cyclophosphamide as graft-versus-host disease prophylaxisR Crocchiolo, S Bramanti, A Vai, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 28, 2002
Intensified CHOP regimen in aggressive lymphomas: maximal dose intensity and dose density of doxorubicin and cyclophosphamideM Balzarotti, M Spina, B Sarina, et al.
Bone Marrow Transplantation|April 29, 2018
CD3+ graft cell count influence on chronic GVHD in haploidentical allogeneic transplantation using post-transplant cyclophosphamideA Mussetti, C De Philippis, C Carniti, et al.
Bone Marrow Transplantation|February 8, 2018
Corrigendum: Disease status is a more reliable predictive factor than histology in lymphoma patients after reduced-intensity conditioning regimen and allo-SCTL Castagna, R Boubdallah, S Furst, et al.
Bone Marrow Transplantation|December 11, 2012
Disease status is a more reliable predictive factor than histology in lymphoma patients after reduced-intensity conditioning regimen and allo-SCTL Castagna, R Boubdallah, S Furst, et al.
Bone Marrow Transplantation|August 7, 2012
Long-term survival in patients with metastatic breast cancer receiving intensified chemotherapy and stem cell rescue: data from the Italian registryM Martino, A Ballestrero, A Zambelli, et al.
Bone Marrow Transplantation|July 8, 2014
Reduced-intensity conditioning regimen with in vivo T-cell depletion for patients with haematological malignancies: results using unrelated and sibling donorsL Castagna, R Crocchiolo, S Furst, et al.
Bone Marrow Transplantation|January 27, 2015
High-dose melphalan with autologous stem cell support in refractory Hodgkin lymphoma patients as a bridge to second transplantL Castagna, R Crocchiolo, L Giordano, et al.
Bone Marrow Transplantation|November 25, 2014
B-cell reconstitution recapitulates B-cell lymphopoiesis following haploidentical BM transplantation and post-transplant CYA Roberto, L Castagna, S Gandolfi, et al.
Pageof 10

Showing results (61-70 of 91) with videos related to

Sort By:
Pageof 10
Leukemia|September 20, 2014
Allogeneic and autologous stem cell transplantation for hepatosplenic T-cell lymphoma: a retrospective study of the EBMT Lymphoma Working PartyA Tanase, N Schmitz, H Stein, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society|February 5, 2015
Infections after T-replete haploidentical transplantation and high-dose cyclophosphamide as graft-versus-host disease prophylaxisR Crocchiolo, S Bramanti, A Vai, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 28, 2002
Intensified CHOP regimen in aggressive lymphomas: maximal dose intensity and dose density of doxorubicin and cyclophosphamideM Balzarotti, M Spina, B Sarina, et al.
Bone Marrow Transplantation|April 29, 2018
CD3+ graft cell count influence on chronic GVHD in haploidentical allogeneic transplantation using post-transplant cyclophosphamideA Mussetti, C De Philippis, C Carniti, et al.
Bone Marrow Transplantation|February 8, 2018
Corrigendum: Disease status is a more reliable predictive factor than histology in lymphoma patients after reduced-intensity conditioning regimen and allo-SCTL Castagna, R Boubdallah, S Furst, et al.
Bone Marrow Transplantation|December 11, 2012
Disease status is a more reliable predictive factor than histology in lymphoma patients after reduced-intensity conditioning regimen and allo-SCTL Castagna, R Boubdallah, S Furst, et al.
Bone Marrow Transplantation|August 7, 2012
Long-term survival in patients with metastatic breast cancer receiving intensified chemotherapy and stem cell rescue: data from the Italian registryM Martino, A Ballestrero, A Zambelli, et al.
Bone Marrow Transplantation|July 8, 2014
Reduced-intensity conditioning regimen with in vivo T-cell depletion for patients with haematological malignancies: results using unrelated and sibling donorsL Castagna, R Crocchiolo, S Furst, et al.
Bone Marrow Transplantation|January 27, 2015
High-dose melphalan with autologous stem cell support in refractory Hodgkin lymphoma patients as a bridge to second transplantL Castagna, R Crocchiolo, L Giordano, et al.
Bone Marrow Transplantation|November 25, 2014
B-cell reconstitution recapitulates B-cell lymphopoiesis following haploidentical BM transplantation and post-transplant CYA Roberto, L Castagna, S Gandolfi, et al.
Pageof 10